Celldex Therapeutics (CLDX) SVP & General Counsel Sells 4,166 Shares

Rhea-AI Filing Summary

Celldex Therapeutics officer Freddy A. Jimenez reported selling 4,166 shares of Celldex Therapeutics, Inc. common stock on December 4, 2025 at $29.095 per share. Following this sale, he directly owns 30,796 shares. The report identifies him as the company’s Senior Vice President and General Counsel and indicates the Form 4 was filed for a single reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jimenez Freddy A.

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NJ 08827

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & GENERAL COUNSEL

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/04/2025		S		4,166	D	$29.095	30,796	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Sam Martin, attorney-in-fact for Freddy A. Jimenez	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Celldex Therapeutics (CLDX) report in this Form 4?

The filing reports that company officer Freddy A. Jimenez sold 4,166 shares of Celldex Therapeutics, Inc. common stock on December 4, 2025.

At what price were the Celldex Therapeutics (CLDX) shares sold by the insider?

The 4,166 shares of Celldex Therapeutics, Inc. common stock were sold at a price of $29.095 per share.

How many Celldex Therapeutics (CLDX) shares does the insider own after the sale?

After the reported sale, Freddy A. Jimenez directly owns 30,796 shares of Celldex Therapeutics, Inc. common stock.

What is the role of the reporting person at Celldex Therapeutics (CLDX)?

The reporting person, Freddy A. Jimenez, is identified as an officer of Celldex Therapeutics, Inc., serving as Senior Vice President & General Counsel.

Was the Celldex Therapeutics (CLDX) Form 4 filed by more than one reporting person?

No. The Form 4 indicates it was filed by one reporting person, not a group.

What type of security was involved in the Celldex Therapeutics (CLDX) insider transaction?

The transaction involved Celldex Therapeutics, Inc. common stock reported in Table I for non-derivative securities.